Evestia Clinical Limited

Evestia Clinical Limited, based in the UK, is a clinical research organization that specializes in delivering a wide range of services for clinical trials across various therapeutic areas, including oncology and rare diseases. Founded in 1996, Evestia Clinical Limited operates as a Clinical Research Organisation (CRO) that provides comprehensive support for clinical trials. The company is headquartered in Letchworth Garden City, UK. In December 2024, Kester Capital acquired Evestia Clinical Limited from Bionical Emas, enhancing their business development capabilities.

In December 2024, Kester Capital, alongside company's management team acquired Evestia Clinical Limited from Bionical Emas. Financial terms were not disclosed. Evestia Clinical is a global specialist Clinical Research Organisation (CRO) that focuses on providing a comprehensive suite of services tailored to the complexities of clinical trials, particularly in areas such as oncology, rare diseases, neurology, immunology, and inflammation. Their core offerings include project management, site management, regulatory services, clinical monitoring, data management and biostatistics, medical affairs and writing, quality assurance, and pharmacovigilance.

These services are designed to navigate the intricate landscape of clinical trials, ensuring that clients—primarily biotechnology firms and pharmaceutical companies—receive expert guidance to accelerate their clinical development processes. Evestia Clinical serves a diverse client base across multiple geographical markets including North America, Europe, and Asia, facilitating clinical research that impacts global health outcomes. Evestia Clinical generates revenue through a variety of transaction structures, primarily engaging in B2B partnerships with biotech and pharmaceutical companies. Their revenue model is centered around the provision of services on a contractual basis, where clients engage the firm for specific projects or ongoing support throughout the clinical trial lifecycle.

This can involve fixed-fee arrangements or retainer agreements based on the scope of work required. The nature of their services allows for tailored pricing plans that reflect the complexity and duration of the clinical trials they manage, alongside specialized services such as regulatory consultancy and data analysis. Each project and client engagement is designed to optimize the clinical research process, ensuring that Evestia Clinical remains a pivotal partner in the advancement of medical innovation. Looking ahead, Evestia Clinical plans to enhance its service offerings and expand into new geographic regions.

The recent acquisition by Kester Capital is expected to support these initiatives by bolstering business development strategies. Specific markets targeted for expansion include North America and Asia, with efforts to reach these markets by the end of 2025. The acquisition will enable the company to refine its operational capabilities, aligning with their goal to adapt and innovate in response to the evolving landscape of clinical trials.